All In Biotech

Drug Trial Radar · NCT06225596

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Jan 24, 2024

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
BicycleTx LimitedIndustry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, randomized, open-label study. The main objective of the study is to measure the clinical activity and safety of zelenectide pevedotin formally BT8009, in combination with pembrolizumab versus chemotherapy, and as monotherapy in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection for zelenectide pevedotin and is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for locally advanced or metastatic UC.

Conditions

  • Metastatic Urothelial Cancer

Interventions

  • Zelenectide pevedotinDrug

    Participants will receive zelenectide pevedotin on Days 1, 8, and 15 of every 21-day cycle.

  • Zelenectide pevedotinDrug

    Participants will receive zelenectide pevedotin on Days 1 and 8 of every 21-day cycle.

  • PembrolizumabDrug

    Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the zelenectide pevedotin infusion.

  • Gemcitabine + cisplatin Or carboplatinDrug

    Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.

  • AvelumabDrug

    After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST v1.1) by blinded central independent review (BICR) of optimal dose zelenectide pevedotin with pembrolizumab versus chemotherapyTime frame: Up to approximately 4 years
  2. Cohort 2: PFS per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimenTime frame: Up to approximately 4 years
  3. Cohort 2: Objective response rate (ORR) per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimenTime frame: Up to approximately 4 years

Locations

102 sites in 21 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Mount Sinai Medical Center of Florida, Inc.

    Miami Beach, Florida

  • Moffitt

    Tampa, Florida

  • University of Kansas Cancer Center

    Westwood, Kansas

  • UofL Health Brown Cancer Center

    Louisville, Kentucky

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Montefiore Medical Center

    The Bronx, New York

  • Medical University of South Carolina (MUSC) - Hollings Cancer Center

    Charleston, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • SCRI Oncology Partners

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Centro de Diagnostico Urologico S.R.L.

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Sirio Libanes de Buenos Aires

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Fundacion Medica Rio Negro y Neuquen

    Cipolletti, Argentina

  • Centro Medico Privado (CEMAIC)

    Córdoba, Argentina

  • Fundación CORI para la investigación y Prevención del Cancer

    La Rioja, Argentina

  • Centro De Investigacion Pergamino S.A.

    Pergamino, Argentina

  • Instituto de Oncologia de Rosario

    Santa Fe, Argentina

  • Clinica Viedma S.A.

    Viedma, Argentina

  • Cancer Research SA

    Adelaide, Australia

  • Mater Misericordiae Ltd, South Brisbane

    Brisbane, Australia

  • Townsville Hospital and Health Service

    Douglas, Australia

  • Barwon Health

    Geelong, Australia

  • Calvary Mater Newcastle

    Hunter, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Blacktown Hospital

    New South Wales, Australia

  • Icon Cancer Centre

    South Brisbane, Australia

  • Gold Coast University Hospital

    Southport, Australia

  • General Hospital Maria Middelares

    Ghent, Belgium

  • University Hospital Gent

    Ghent, Belgium

  • Fundacao PIO XII - Hospital de Amor

    Barretos, Brazil

  • CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina

    Florianópolis, Brazil

  • Hospital Alemao Oswaldo Cruz

    São Paulo, Brazil

  • McGill University Health Center

    Québec, Canada

  • Princess Margaret Hospital

    Toronto, Canada

  • Fundación Arturo López Pérez (FALP)

    Santiago, Chile

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.